

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0104			
Estimated average burden				
nours per respons	e 0.5			

#### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Fillit of Type Responses)					
Name and Address of Reporting Person * HARDY REGINALD L	2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol Brickell Biotech, Inc. [BBI]			
(Last) (First) (Middle) C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102	Issuer		p of Reporting Person(s) to eck all applicable) 10% Owner		5. If Amendment, Date Original Filed(Month/Day/Year)
BOULDER, CO 80301		X Officer (give title below)  Chairman of the Board			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned				
1.Title of Security (Instr. 4)	2. Amount of S Beneficially Ov (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Natur (Instr. 5	re of Indirect Beneficial Ownership
Common Stock	168,423	168,423			
Common Stock	9,261	9,261		By Spouse	
Common Stock	21,826	21,826		By Spouse (spouse jointly owns with other Individual)	
Common Stock	17,260	17,260		By Spouse as Trustee	
Common Stock	266,447	266,447		By Self as General Partner	
Common Stock	17,260		I	By Sel	f as Trustee

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security 5. Ownership 6. Nature of Indirect 2. Date Exercisable and 3. Title and Amount of 4. Conversion (Instr. 4) **Expiration Date** Securities Underlying or Exercise Form of Beneficial Ownership (Month/Day/Year) Derivative Security Derivative Price of (Instr. 5) (Instr. 4) Derivative Security: Direct (D) or Security Expiration Date Amount or Indirect (I) Title Exercisable Date Number of Shares (Instr. 5) Common 04/22/2025 12,082 Stock Options 04/22/2015 \$ 12.17 D Stock Common **Stock Options** 12/23/2015 12/23/2025 12,082 \$ 12.17 D Stock Common **Stock Options** 12/15/2016 12/15/2026 3,452 \$ 12.17 D Stock Common Stock Options 11/27/2018 12/15/2027 2,761 \$ 16.69 D Stock Common 12/15/2019 12/15/2028 5,178 \$ 16.45 D Stock Options Stock Common Stock Options 08/30/2020 08/30/2029 51,782 \$ 4.76 D Stock Common By Self as General 08/30/2019 08/30/2029 19,899 \$ 10.36 Ι Warrants Stock Partner Common Warrants 08/30/2019 08/30/2029 3,316 \$ 10.36 I By Spouse Stock

### **Reporting Owners**

Relationships

Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
HARDY REGINALD L C/O BRICKELL BIOTECH, INC. 5777 CENTRAL AVENUE, SUITE 102 BOULDER, CO 80301	X		Chairman of the Board		

# **Signatures**

/s/ Reginald L. Hardy	09/09/2019
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.